WO1999058118A3 - METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES - Google Patents

METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES Download PDF

Info

Publication number
WO1999058118A3
WO1999058118A3 PCT/IB1999/001285 IB9901285W WO9958118A3 WO 1999058118 A3 WO1999058118 A3 WO 1999058118A3 IB 9901285 W IB9901285 W IB 9901285W WO 9958118 A3 WO9958118 A3 WO 9958118A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
oligonucleotides
cpg
hematopoiesis
regulating
Prior art date
Application number
PCT/IB1999/001285
Other languages
French (fr)
Other versions
WO1999058118A2 (en
Inventor
Hermann Wagner
Grayson Lipford
Original Assignee
Cpg Immunopharmaceuticals Gmbh
Cpg Immunopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ508650A priority Critical patent/NZ508650A/en
Priority to DE69927495T priority patent/DE69927495T2/en
Priority to EP99928176A priority patent/EP1078053B1/en
Priority to AT99928176T priority patent/ATE305507T1/en
Priority to AU45288/99A priority patent/AU760795B2/en
Priority to JP2000547969A priority patent/JP2002514397A/en
Application filed by Cpg Immunopharmaceuticals Gmbh, Cpg Immunopharmaceuticals Inc filed Critical Cpg Immunopharmaceuticals Gmbh
Priority to IL13964699A priority patent/IL139646A0/en
Priority to CA002328406A priority patent/CA2328406A1/en
Publication of WO1999058118A2 publication Critical patent/WO1999058118A2/en
Publication of WO1999058118A3 publication Critical patent/WO1999058118A3/en
Priority to IL139646A priority patent/IL139646A/en
Priority to IL187987A priority patent/IL187987A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to methods for regulating hematopoiesis using CpG containing oligonucleotides. In particular, the invention relates to methods of treating thrombopoiesis and anemia by regulating hematopoiesis. The invention also relates to method of regulating immune system remodelling by administering CpG oligonucleotides to control hematopoiesis.
PCT/IB1999/001285 1998-05-14 1999-05-14 METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES WO1999058118A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE69927495T DE69927495T2 (en) 1998-05-14 1999-05-14 METHOD OF REGULATING HEMATOPOESIS BY USING CPG OLIGONUCLEOTIDES
EP99928176A EP1078053B1 (en) 1998-05-14 1999-05-14 METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
AT99928176T ATE305507T1 (en) 1998-05-14 1999-05-14 METHOD FOR REGULATING HEMATOPOIESIS USING CPG OLIGONUCLEOTIDES
AU45288/99A AU760795B2 (en) 1998-05-14 1999-05-14 Methods for regulating hematopoiesis using CpG-oligonucleotides
JP2000547969A JP2002514397A (en) 1998-05-14 1999-05-14 Methods for hematopoietic regulation using CpG oligonucleotides
NZ508650A NZ508650A (en) 1998-05-14 1999-05-14 Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
IL13964699A IL139646A0 (en) 1998-05-14 1999-05-14 Methods for regulating hematopoiesis using cpg-oligonucleotides
CA002328406A CA2328406A1 (en) 1998-05-14 1999-05-14 Methods for regulating hematopoiesis using cpg-oligonucleotides
IL139646A IL139646A (en) 1998-05-14 2000-11-13 USE OF A CpG OLIGONUCLEOTIDE TO PREPARE A MEDICAMENT FOR INDUCING AN ANTIGEN - SPECIFIC IMMUNE RESPONSE
IL187987A IL187987A0 (en) 1998-05-14 2007-12-06 Use of a cpg oligonucleotide to prepare a medicament for inducing an antigen-specific immune response

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8551698P 1998-05-14 1998-05-14
US24165399A 1999-02-02 1999-02-02
US09/241,653 1999-02-02
US60/085,516 1999-02-02

Publications (2)

Publication Number Publication Date
WO1999058118A2 WO1999058118A2 (en) 1999-11-18
WO1999058118A3 true WO1999058118A3 (en) 2000-01-13

Family

ID=26772811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/001285 WO1999058118A2 (en) 1998-05-14 1999-05-14 METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES

Country Status (10)

Country Link
US (5) US20040030118A1 (en)
EP (2) EP1078053B1 (en)
JP (1) JP2002514397A (en)
AT (1) ATE305507T1 (en)
AU (1) AU760795B2 (en)
CA (1) CA2328406A1 (en)
DE (1) DE69927495T2 (en)
IL (3) IL139646A0 (en)
NZ (1) NZ508650A (en)
WO (1) WO1999058118A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
ATE437943T1 (en) * 1996-01-30 2009-08-15 Univ California EXPRESSION VECTORS THAT INDUCE AN ANTIGEN-SPECIFIC IMMUNE RESPONSE AND METHODS FOR THEIR USE.
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
AU760549B2 (en) * 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
IL139646A0 (en) * 1998-05-14 2002-02-10 Coley Pharm Group Inc Methods for regulating hematopoiesis using cpg-oligonucleotides
SI1077722T1 (en) * 1998-05-22 2007-02-28 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
PT1104306E (en) 1998-08-10 2006-05-31 Antigenics Inc CPG COMPOSITIONS AND SAPONIN ADJUVANTS AND THEIR METHODS
CA2362204C (en) * 1999-02-17 2011-11-08 John Cooper Cox Immunogenic complexes and methods relating thereto
AU4343700A (en) * 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
FR2795963A1 (en) * 1999-07-08 2001-01-12 Pasteur Merieux Serums Vacc New polynucleotides are useful as vaccines for humans
DE60041335D1 (en) * 1999-08-19 2009-02-26 Dynavax Tech Corp METHOD FOR MODULATING AN IMMUNE RESPONSE WITH IMMUNOSTIMULATING SEQUENCES AND COMPOSITIONS THEREFOR
CN1454091A (en) * 1999-09-25 2003-11-05 衣阿华大学研究基金会 Immunostimulatory nucleic acids
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US7157437B2 (en) * 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20020107212A1 (en) * 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
SI1296714T1 (en) * 2000-06-22 2010-01-29 S For Entpr University Of Iowa Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
WO2002002172A1 (en) * 2000-06-30 2002-01-10 Univ Jefferson Dna palindrome - oligoguanylic acid compositions and uses thereof
KR100917101B1 (en) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 Flexible metal laminate and production method thereof
JP2005500806A (en) 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー Process for high-throughput screening of immune agonist / immunoantagonists based on CpG
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
AU2002248185A1 (en) * 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
US9777312B2 (en) 2001-06-30 2017-10-03 Enzo Life Sciences, Inc. Dual polarity analysis of nucleic acids
ES2314099T3 (en) 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh IMMUNO STIMULANT OLIGONUCLEOTIDES WITH REASONS COMBINED WITH IMPROVED ACTIVITY.
US20030091593A1 (en) * 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
ATE447967T1 (en) 2001-09-14 2009-11-15 Cytos Biotechnology Ag PACKAGING OF IMMUNO-STIMULATIVE CPG IN VIRUS-LIKE PARTICLES: PRODUCTION METHOD AND USE
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found Methods and products for enhancing immune responses using imidazoquinoline compounds
ES2734652T3 (en) 2002-04-04 2019-12-11 Zoetis Belgium S A Immunostimulatory oligonucleotides containing G and U
KR20050009697A (en) 2002-04-22 2005-01-25 바이오니취 라이프 사이언시즈 인코포레이티드 Oligonucleotide compositions and their use for the modulation of immune responses
BR0311995A (en) * 2002-06-20 2005-04-05 Cytos Biotechnology Ag Virus-like particles packaged for use as adjuvants: Method of preparation and use
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
JP2005532067A (en) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド Nucleic acid composition for stimulating immune response
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20050209183A1 (en) * 2002-07-25 2005-09-22 Phenion Gmbh & Co. Kg Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated CPG motifs
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
SI2241325T1 (en) * 2002-10-29 2012-05-31 Coley Pharm Group Inc Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
WO2004053104A2 (en) * 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
NZ542323A (en) * 2003-03-26 2008-07-31 Cytos Biotechnology Ag Melan-A peptide analogue-virus-like-particle conjugates
WO2004100965A1 (en) * 2003-05-15 2004-11-25 Japan Science And Technology Agency Immunostimulant
EP1635846A4 (en) * 2003-06-20 2009-01-28 Coley Pharm Gmbh Small molecule toll-like receptor (tlr) antagonists
WO2005004907A1 (en) * 2003-07-10 2005-01-20 Cytos Biotechnology Ag Packaged virus-like particles
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
JP2007531699A (en) * 2003-07-15 2007-11-08 イデラ ファーマシューティカルズ インコーポレイテッド Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and / or immunomeric compounds in combination with cytokines and / or chemotherapeutic agents or radiation therapy
US7615539B2 (en) * 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US8188254B2 (en) * 2003-10-30 2012-05-29 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
EP2415481A3 (en) * 2004-02-19 2012-04-18 Coley Pharmaceutical Group, Inc. Immunostimulatory viral RNA oligonucleotides
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
CA2567789A1 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
EP1781325A2 (en) * 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
CA2598992A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
US20060229271A1 (en) * 2005-04-08 2006-10-12 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
CA2609788A1 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
CA2612162C (en) 2005-07-01 2016-05-17 Index Pharmaceuticals Ab Use of oligonucleotides in steroid refractory or steroid dependent inflammatory conditions
EP2179737B1 (en) 2005-07-01 2013-08-14 Index Pharmaceuticals AB Modulating responsiveness to steroids
SG163583A1 (en) * 2005-07-07 2010-08-30 Coley Pharm Group Inc Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
EP1924692A2 (en) * 2005-09-16 2008-05-28 Coley Pharmaceutical GmbH Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
EA013468B1 (en) * 2005-09-16 2010-04-30 Коли Фармасьютикал Гмбх Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
AU2006306805A1 (en) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
EP1957647B1 (en) * 2005-11-25 2015-03-04 Zoetis Belgium S.A. Immunostimulatory oligoribonucleotides
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
CA2642152C (en) * 2006-02-15 2016-11-01 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations
MX2008015529A (en) 2006-06-12 2009-01-13 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages.
CN101517082B (en) 2006-09-27 2014-01-22 科勒制药有限责任公司 Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2008057529A2 (en) * 2006-11-06 2008-05-15 Coley Pharmaceutical Group, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
EP3552625A1 (en) 2008-06-27 2019-10-16 Zoetis Services LLC Novel adjuvant compositions
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
ES2616051T3 (en) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Method for the synthesis of modified nucleic acids in the phosphorus atom
PL2411521T3 (en) 2009-03-25 2015-08-31 Univ Texas Compositions for stimulation of mammalian innate immune resistance to pathogens
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
KR101502200B1 (en) * 2011-03-03 2015-03-13 충북대학교 산학협력단 Composition for Stimulating Erythropoiesis Comprising Quercetin 3-O-β-(2＂-galloyl)-rhamnopyranoside As Active Ingredient
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
JP6246121B2 (en) 2012-07-13 2017-12-13 株式会社新日本科学 Chiral nucleic acid adjuvant
MX2015000577A (en) 2012-07-13 2015-08-14 Wave Life Sciences Pte Ltd Chiral control.
CN107011400B (en) 2012-07-13 2021-05-25 波涛生命科学有限公司 Asymmetric auxiliary group
EP3049105B1 (en) 2013-09-19 2020-12-30 Moredun Research Institute Vaccine
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR102423317B1 (en) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 Chiral design
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
CN114699518A (en) 2015-01-16 2022-07-05 硕腾服务有限责任公司 Foot and mouth disease vaccine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1997028259A1 (en) * 1996-01-30 1997-08-07 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
WO1998011211A2 (en) * 1996-09-10 1998-03-19 Hybridon, Inc. METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES
WO1998018810A1 (en) * 1996-10-30 1998-05-07 The University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US5786189A (en) * 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5506212A (en) * 1990-01-11 1996-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5512668A (en) * 1991-03-06 1996-04-30 Polish Academy Of Sciences Solid phase oligonucleotide synthesis using phospholane intermediates
US5498410A (en) * 1991-04-22 1996-03-12 Gleich; Gerald J. Method for the treatment of eosinophil-associated conditions with anionic polymers
US5359052A (en) * 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US5599797A (en) * 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
WO1995014031A1 (en) * 1993-11-16 1995-05-26 Genta Incorporated Chirally enriched synthetic phosphonate oligomers
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AU716486B2 (en) * 1995-04-13 2000-02-24 Milkhaus Laboratory, Inc. Methods for treating respiratory disease
US5750674A (en) * 1995-05-23 1998-05-12 Hybridon, Inc. Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US7034007B1 (en) * 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US20030078223A1 (en) * 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
ES2283015T3 (en) * 1996-04-19 2007-10-16 Merial Ltd. VACCINATION WITH NUCLEIC ACIDS FOR PARVOVIRIC INFECTIONS.
US5856465A (en) * 1996-05-24 1999-01-05 Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
ES2241042T3 (en) * 1996-10-11 2005-10-16 The Regents Of The University Of California IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA.
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6214806B1 (en) * 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) * 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20030104044A1 (en) * 1997-05-14 2003-06-05 Semple Sean C. Compositions for stimulating cytokine secretion and inducing an immune response
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
EP1009440B1 (en) * 1997-07-03 2008-09-17 MacFarlane, Donald E. Method for inhibiting immunostimulatory dna associated responses
AU757175B2 (en) * 1997-09-05 2003-02-06 Regents Of The University Of California, The Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
US6749856B1 (en) * 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
JPH11209289A (en) * 1998-01-22 1999-08-03 Taisho Pharmaceut Co Ltd Mucosal immunity inducer
AU760549B2 (en) * 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU3884199A (en) * 1998-05-06 1999-11-23 Ottawa Health Research Institute Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
IL139646A0 (en) * 1998-05-14 2002-02-10 Coley Pharm Group Inc Methods for regulating hematopoiesis using cpg-oligonucleotides
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
WO2000016804A1 (en) * 1998-09-18 2000-03-30 Dynavax Technologies Corporation METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
CN1454091A (en) * 1999-09-25 2003-11-05 衣阿华大学研究基金会 Immunostimulatory nucleic acids
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
SI1296714T1 (en) * 2000-06-22 2010-01-29 S For Entpr University Of Iowa Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US20020165178A1 (en) * 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en) * 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
US20020091097A1 (en) * 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
JP2005500806A (en) * 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー Process for high-throughput screening of immune agonist / immunoantagonists based on CpG
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
AU2002248185A1 (en) * 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
KR20050034583A (en) * 2001-10-05 2005-04-14 콜리 파마슈티칼 게엠베하 Toll-like receptor 3 signaling agonists and antagonists
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found Methods and products for enhancing immune responses using imidazoquinoline compounds
ES2734652T3 (en) * 2002-04-04 2019-12-11 Zoetis Belgium S A Immunostimulatory oligonucleotides containing G and U
WO2003103586A2 (en) * 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) * 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
SI2241325T1 (en) * 2002-10-29 2012-05-31 Coley Pharm Group Inc Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
JP4976653B2 (en) * 2002-11-01 2012-07-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス Method for preventing infections caused by bioterrorism pathogens using immunostimulatory CpG oligonucleotides
EP1635846A4 (en) * 2003-06-20 2009-01-28 Coley Pharm Gmbh Small molecule toll-like receptor (tlr) antagonists
US7615539B2 (en) * 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
US20060019916A1 (en) * 2004-04-02 2006-01-26 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing IL-10 responses
CA2567789A1 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
CA2574090A1 (en) * 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
CA2598992A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
SG163583A1 (en) * 2005-07-07 2010-08-30 Coley Pharm Group Inc Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
EP1957647B1 (en) * 2005-11-25 2015-03-04 Zoetis Belgium S.A. Immunostimulatory oligoribonucleotides
CA2642152C (en) * 2006-02-15 2016-11-01 Coley Pharmaceutical Gmbh Compositions and methods for oligonucleotide formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1997028259A1 (en) * 1996-01-30 1997-08-07 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
WO1998011211A2 (en) * 1996-09-10 1998-03-19 Hybridon, Inc. METHOD FOR USING OLIGONUCLEOTIDES HAVING MODIFIED CpG DINUCLEOSIDES
WO1998018810A1 (en) * 1996-10-30 1998-05-07 The University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGRAWAL S. ET AL.: "Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats.", ANTISENSE NUCLEIC ACID DRUG DEV 1997 DEC;7(6):575-84, XP002122934 *
G. B. LIPFORD ET AL: "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 12, no. 27, pages 3420-3426, XP002077483, ISSN: 0014-2980 *
JAKOB T. ET AL.: "Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses.", INT ARCH ALLERGY IMMUNOL 1999 FEB-APR;118(2-4):457-61, XP002122936 *
KRIEG AM. ET AL.: "CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge.", J IMMUNOL 1998 SEP 1;161(5):2428-34, XP002122935 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV

Also Published As

Publication number Publication date
NZ508650A (en) 2003-05-30
AU4528899A (en) 1999-11-29
US20070184465A1 (en) 2007-08-09
AU760795B2 (en) 2003-05-22
EP1078053A2 (en) 2001-02-28
CA2328406A1 (en) 1999-11-18
US20040235778A1 (en) 2004-11-25
US20040235777A1 (en) 2004-11-25
DE69927495T2 (en) 2006-07-06
IL139646A0 (en) 2002-02-10
EP1674574A1 (en) 2006-06-28
WO1999058118A2 (en) 1999-11-18
EP1078053B1 (en) 2005-09-28
US20040234512A1 (en) 2004-11-25
IL139646A (en) 2008-03-20
ATE305507T1 (en) 2005-10-15
IL187987A0 (en) 2008-03-20
JP2002514397A (en) 2002-05-21
US20040030118A1 (en) 2004-02-12
DE69927495D1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO1999058118A3 (en) METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
AU4612093A (en) Soluble ligands for CD40
HK1034039A1 (en) Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999004752A3 (en) Methods for treating skin pigmentation
WO2001010381A3 (en) Methods for treating or preventing pain and anxiety
WO2003027313A3 (en) SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
HK1049266A1 (en) Method and compostion for the control of arthropods.
EP1190099A4 (en) Antisense modulation of pi3k p85 expression
BG100960A (en) Dosage forms for controlled release of azitromycin
AU5317596A (en) Emulsified, low ph cosmetic compositions having improved stability
GR3024597T3 (en) 7-deazapurine modified oligonucleotides
GR3023508T3 (en) Paramunity inducer based ou combinations of poxvirus components, process to prepore it and its use as medicament.
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
WO1999059617A3 (en) Immunoregulator
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
HK1020166A1 (en) Method to increase retinal blood flow.
AU2094200A (en) Cosmetic or medical preparation for topical use
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
ZA9610849B (en) Methods and compositions for controlling biofouling using fluorosurfactants.
AU3893493A (en) Micro-organisms, preparation method therefor and uses thereof
EP0645454A3 (en) Chimeric somatostatin containing protein and coding DNA, immunogenic compositions and method for increasing farm animal productivity.
EP1390388A4 (en) Antisense modulation of interferon gamma receptor 1 expression
HK1029919A1 (en) Method for preventing the misuse of a transdermal therapeutic system
AU2001288236A1 (en) Natural, non-allergenic, immune system stimulant
MX9603342A (en) Piranes-4h-substituted.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2328406

Country of ref document: CA

Ref country code: CA

Ref document number: 2328406

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 139646

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 45288/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200007071

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 508650

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1999928176

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999928176

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 45288/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999928176

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 187987

Country of ref document: IL